Table 5.

Multivariable survival analysis stratified by stage and status in terms of chemotherapy for stage III high risk.

			Overall survival (years from diagnosis)
Covariate	Level	N	Hazard ratio (95% CI)	HR P-value
Chemotherapy type	No chemo	9191	2.40 (2.29-2.52)	<.001
	Single agent	2995	1.13 (1.07-1.20)	<.001
	Multiagent	6014	NA	NA
Facility type	Community cancer program	2381	1.15 (1.08-1.23)	<.001
	Comprehensive community cancer program	9040	1.07 (1.02-1.12)	.004
	Integrated network cancer program	2688	1.11 (1.04-1.18)	.001
	Academic/research Program	4091	NA	NA
Facility location	Northeast	4348	0.98 (0.93-1.04)	.542
	South	6005	1.08 (1.02-1.14)	.009
	Midwest	4924	1.04 (0.99-1.11)	.141
	West	2923	NA	NA
Grade	Moderately differentiated, moderately well differentiated, and intermediate differentiation	9836	0.98 (0.90-1.07)	0.627
	Poorly differentiated	6444	1.24 (1.14-1.36)	<.001
	Undifferentiated, anaplastic	1062	1.41 (1.27-1.57)	<.001
	Well differentiated and differentiated, NOS	858	NA	NA
Race	Black	1498	1.00 (0.94-1.07)	.929
	Other	668	0.82 (0.74-0.91)	<.001
	White	16 034	NA	NA
Hispanic ethnicity	Yes	776	0.83 (0.75-0.91)	<.001
	No	17 424	NA	NA
Insurance type	Not insured	101	0.96 (0.74-1.26)	.791
	Private insurance	1686	0.99 (0.93-1.06)	.803
	Government insurance	16 413	NA	NA
Surgical margins	Positive	2671	1.68 (1.60-1.76)	<.001
	Negative	15 529	NA	NA
Charlson-Deyo scores	1	4674	1.13 (1.09-1.18)	<.001
	≥2	2243	1.39 (1.32-1.47)	<.001
	0	11 283	NA	NA
Year of diagnosis	2007-2009	2920	0.98 (0.93-1.04)	.567
	2010-2012	5725	0.95 (0.90-1.00)	.059
	2013-2015	6383	0.93 (0.88-0.98)	.010
	2004-2006	3172	NA	NA
Tumor size	2-4 cm	5582	1.00 (0.90-1.12)	.937
	>4 cm	12042	1.06 (0.95-1.17)	.291
	≤2 cm	576	NA	NA
Age at diagnosis		18 200	1.02 (1.02-1.03)	<.001